Wedbush Reiterates Outperform on BridgeBio Oncology, Maintains $25 Price Target

Benzinga Newsdesk www.benzinga.com Positive 47.9%

Neg 0% Neu 0% Pos 47.9%

Wedbush analyst David Nierengarten reiterates BridgeBio Oncology (NASDAQ:BBOT) with a Outperform and maintains $25 price target.